Innovating.works Conecta tu I+D

Inno4Vac: Innovations to accelerate vaccine development and manufacture SANOFI PASTEUR SA participó en un H2020: H2020-JTI-IMI2-2020-20-two-stage Inno4Vac proposes an ambitious programme that will harness the latest advances in immunology, disease modelling, and modelling for tackling...
2021-07-19 - 2027-02-28 | Financiado

PROMISE: Preparing for RSV Immunisation and Surveillance in Europe SANOFI PASTEUR SA participó en un H2020: H2020-JTI-IMI2-2020-22-single-stage RSV causes severe disease in the very young and elderly and results in substantial healthcare costs. In the last 4 years, substantial progre...
2021-05-21 - 2024-04-30 | Financiado

VITAL: Vaccines and Infectious Diseases in the Ageing PopuLation SANOFI PASTEUR SA participó en un H2020: H2020-JTI-IMI2-2017-12-two-stage Today’s major challenge is to improve efficacy of vaccines to protect the growing ageing population against infectious diseases (ID). The VI...
2018-12-10 - 2024-12-31 | Financiado

COMBACTE-CDI: Combatting Bacterial Resistance in Europe Clostridium Difficile Infections SANOFI PASTEUR SA participó en un H2020: H2020-JTI-IMI2-2016-09-two-stage Clostridium difficile infection (CDI) is one of the most prevalent healthcare associated infections, affecting both hospitalized patients an...
2017-10-27 - 2021-04-30 | Financiado

DRIVE: Development of Robust and Innovative Vaccine Effectiveness SANOFI PASTEUR SA participó en un H2020: H2020-JTI-IMI2-2016-09-two-stage Influenza is a major public health problem. In a conservative estimate, influenza infects annually 60 of the 500 million inhabitants of the...
2017-08-08 - 2022-06-30 | Financiado

RESCEU: REspiratory Syncytial virus Consortium in EUrope Sofia ref. 116019 SANOFI PASTEUR SA participó en un H2020: H2020-JTI-IMI2-2015-06-two-stage RSV causes severe disease and results in substantial healthcare costs in individuals at the extremes of the age spectrum and in high risk gr...
2016-12-14 - 2022-09-30 | Financiado

PERISCOPE: PERtussIS COrrelates of Protection Europe Sofia ref. 115910 SANOFI PASTEUR SA participó en un H2020: H2020-JTI-IMI2-2015-03-two-stage Pertussis vaccines have been very successful in reducing the global burden of pertussis-related disease. However, in the last decade there h...
2016-08-01 - 2022-08-31 | Financiado

VAC2VAC: Vaccine lot to Vaccine lot comparison by consistency testing. SANOFI PASTEUR SA participó en un H2020: H2020-JTI-IMI2-2015-03-two-stage Lot release testing of established vaccines relies on using animal models. Many of these models were developed decades ago and reflect the l...
2016-04-14 - 2022-02-28 | Financiado

EHVA: European HIV Vaccine Alliance EHVA a EU platform for the discovery and evaluation of novel prophy... SANOFI PASTEUR SA participó en un H2020: H2020-PHC-2014-2015 Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. T...
2015-12-17 - 2023-12-31 | Financiado

FLUCOP: Standardization and Development of Assays for Assessment of Influenza Vaccines Correlates of Protect... SANOFI PASTEUR SA tramitó un FP6: Background: Influenza viruses cause annual epidemic and occasional pandemics, both of which induce significant morbidity and mortality. Infl...
2015-03-01 - 2020-02-29 | Financiado

ADVANCE: Accelerated Development of Vaccine benefit-risk Collaboration in Europe SANOFI PASTEUR SA participó en un FP6: Aim: The ADVANCE vision is focused on Timely and Best Evidence on Vaccine Effects. Our mission is to establish a best practice framework to...
2013-10-01 - 2019-03-31 | Financiado

BIOVACSAFE: Biomarkers For Enhanced Vaccine Safety SANOFI PASTEUR SA participó en un FP6: BioVacSafe is a concise consortium of selected academic, public, and SME participants used to co-working in industry-led projects, organised...
2012-03-01 - 2018-08-31 | Financiado

FLUCOP: Standardization and Development of Assays for Assessment of Influenza Vaccines Correlates of Protect... SANOFI PASTEUR SA tramitó un FP7: Background: Influenza viruses cause annual epidemic and occasional pandemics, both of which induce significant morbidity and mortality. Infl...
Financiado

EURONEUT-41: EUROpean consortium on NEUTralising antibodies using gp41 SANOFI PASTEUR SA tramitó un FP7: There is now an increasingly solid body of scientific evidence which demonstrates that the binding of small molecular weight compounds, pept...
Financiado

STOPENTERICS: Vaccination against Shigella and ETEC novel antigens novel approaches SANOFI PASTEUR SA participó en un FP7: To contribute to the development of vaccines against Shigella and ETEC for children of the developing world, STOPENTERICS will provide novel...
Financiado

ADVANCE: Accelerated Development of Vaccine benefit risk Collaboration in Europe SANOFI PASTEUR SA participó en un FP7: Aim: The ADVANCE vision is focused on Timely and Best Evidence on Vaccine Effects. Our mission is to establish a best practice framework to...
Financiado

BIOVACSAFE: Biomarkers For Enhanced Vaccine Safety SANOFI PASTEUR SA participó en un FP7: BioVacSafe is a concise consortium of selected academic, public, and SME participants used to co-working in industry-led projects, organised...
Financiado